Article
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 2 May 2018
Raymond Stéphanie, Nicot Florence, Pallier Coralie, Bellecave Pantxika, Maillard Anne, Trabaud Mary Anne, Morand-Joubert Laurence, Rodallec Audrey, Amiel Corinne, Mourez Thomas, Bocket Laurence, Beby-Defaux Agnès, Bouvier-Alias Magali, Lambert-Niclot Sidonie, Charpentier Charlotte, Malve Brice, Mirand Audrey, Dina Julia, Le Guillou-Guillemette Hélène, Marque-Juillet Stéphanie, Signori-Schmuck Anne, Barin Francis, Si-Mohamed Ali, Avettand Fenoel Véronique, Roussel Catherine, Calvez Vincent, Saune Karine, Marcelin Anne Geneviève, Rodriguez Christophe, Descamps Diane, Izopet Jacques
Abstract excerpt
Background: Minority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t)ide reverse transcriptase...
Topics
- Adult
- Drug Resistance, Viral
- Female
- Genetic Variation
- HIV Infections
- HIV-1
